| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_620939cea0c53e7263e5c04588ec80bb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-83 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0226
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2-0023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L2-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-755 |
| filingDate |
1981-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_149ea561ee4b375df8ce734b253903b8 |
| publicationDate |
1982-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0053046-A1 |
| titleOfInvention |
Stabilisation of factor VIII activity in blood plasma |
| abstract |
Fresh blood plasma that has been collected in the presence of a calcium chelating anticoagulant from fresh whole blood or by plasmapheresis is treated to stabilise its Factor VIII activity. The method resides in adding dissolved calcium and dissolved heparin to the freshly collected plasma in an amount sufficient to stabilise significantly the Factor VIII activity, the amount of calcium generally being sufficient substantially to restore the calcium in the blood plasma to substantially normal physiological levels and the amount of heparin generally being from 4 to 8 units per ml. Novel compositions of calcium and heparin are described. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5422250-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0431385-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0416983-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0441695-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-8808004-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0106269-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0106269-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2657884-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2651437-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5679776-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0077119-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/HR-P920768-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0077119-A3 |
| priorityDate |
1980-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |